搜索
Protalix Biotherapeutics Inc
PLX添加自选
2.395USD
+0.025+1.05%
收盘 07-27 16:00（美东）报价延迟15分钟
192.97M总市值
12.40市盈率 TTM
关于 Protalix Biotherapeutics Inc 公司
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Protalix Biotherapeutics Inc简介
公司代码PLX
公司名称Protalix Biotherapeutics Inc
上市日期Sep 06, 2010
CEOBashan (Dror)
员工数量207
证券类型Ordinary Share
年结日Sep 06
公司地址2 University Plaza
城市HACKENSACK
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编07601
电话12016969345
网址https://protalix.com/
公司代码PLX
上市日期Sep 06, 2010
CEOBashan (Dror)
Protalix Biotherapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.53M
+7.70%
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
310.50K
+2.42%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
232.30K
+10.76%
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
7.54K
+99.47%
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
7.50K
+99.47%
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
3.63K
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.53M
+7.70%
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
310.50K
+2.42%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
232.30K
+10.76%
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
7.54K
+99.47%
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
7.50K
+99.47%
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
3.63K
--
常见问题
Protalix Biotherapeutics Inc的前五大股东是谁？
Protalix Biotherapeutics Inc 的前五大股东如下：Mr. Dror Bashan
有多少机构持有Protalix Biotherapeutics Inc(PLX)的股份？
截至2026Q1，共有193家机构持有Protalix Biotherapeutics Inc的股份，合计持有的股份价值约为19.91M，占公司总股份的24.71%。与2025Q4相比，机构持股有所增加，增幅为2149424.00。